It has been reviewed that as many as hundreds genes are dysregulated in various kinds of cancers, yet most therapies are targeted toward a single gene.  Recently, the mode of cancer treatment has been changed by a shift in thinking from mono-target to multi-target therapies.  There is considerable evidence that these have a higher possibility of success than mono-target therapy, and multi-target therapy should remain the most     attractive avenue for future treatment strategies.  In this article, we attempt to provide evidence for the role of small interfering RNA in multi-target therapy of cancer.